BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33389584)

  • 1. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
    Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
    Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations and prognosis in primary myelofibrosis.
    Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
    Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CALR mutation screening in pediatric primary myelofibrosis.
    An W; Wan Y; Guo Y; Chen X; Ren Y; Zhang J; Chang L; Wei W; Zhang P; Zhu X
    Pediatr Blood Cancer; 2014 Dec; 61(12):2256-62. PubMed ID: 25176567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients.
    Kim TY; Kwag D; Lee JH; Lee J; Min GJ; Park SS; Park S; Jeon YW; Yoon JH; Shin SH; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Cho SG; Lee JW; Lee JM; Kim M; Lee SE
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
    Tefferi A; Lasho TL; Finke CM; Knudson RA; Ketterling R; Hanson CH; Maffioli M; Caramazza D; Passamonti F; Pardanani A
    Leukemia; 2014 Jul; 28(7):1472-7. PubMed ID: 24402162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.
    Zhang L; Ye X; Luo S; Xu X; Wang S; Jin K; Zheng Y; Zhu X; Chen D; Jin J; Huang J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2383-2392. PubMed ID: 35731275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
    Salit RB; Deeg HJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
    Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
    Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
    Loscocco GG; Rotunno G; Mannelli F; Coltro G; Gesullo F; Pancani F; Signori L; Maccari C; Esposito M; Paoli C; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2024 Jan; 99(1):68-78. PubMed ID: 37846894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
    Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
    J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
    Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
    Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
    Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
    Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis.
    Bartels S; Faisal M; Büsche G; Schlue J; Hasemeier B; Schipper E; Vogtmann J; Westphal L; Lehmann U; Kreipe H
    Leukemia; 2020 May; 34(5):1364-1372. PubMed ID: 31776465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of Primary Myelofibrosis in the Genomic Era.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
    Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
    Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
    Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
    J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.
    Brecqueville M; Rey J; Devillier R; Guille A; Gillet R; Adélaide J; Gelsi-Boyer V; Arnoulet C; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D; Murati A
    Haematologica; 2014 Jan; 99(1):37-45. PubMed ID: 23996481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.